UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease

PloS one, 2010-12, Vol.5 (12), p.e14192-e14192

2010

Volltextzugriff (PDF)

Study of Telomere Length Reveals Rapid Aging of Human Marrow Stromal Cells following In Vitro Expansion

Stem cells (Dayton, Ohio), 2004-09, Vol.22 (5), p.675-682

2004

Volltextzugriff (PDF)

Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB

PloS one, 2012-04, Vol.7 (4), p.e35787-e35787

2012

Volltextzugriff (PDF)

A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow

Blood, 2004-11, Vol.104 (9), p.2643-2645

2004

Volltextzugriff (PDF)

Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler’s syndrome after pharmacological enzyme replacement therapy

Haematologica (Roma), 2012-09, Vol.97 (9), p.1320-1328

2012

Volltextzugriff (PDF)

Improved Metabolic Correction in Patients with Lysosomal Storage Disease Treated with Hematopoietic Stem Cell Transplant Compared with Enzyme Replacement Therapy

The Journal of pediatrics, 2009-04, Vol.154 (4), p.609-611

2009

Volltextzugriff (PDF)

Circadian rhythm and suprachiasmatic nucleus alterations in the mouse model of mucopolysaccharidosis IIIB

Behavioural brain research, 2010-06, Vol.209 (2), p.212-220

2010

Volltextzugriff (PDF)

Signal one and two blockade are both critical for non-myeloablative murine HSCT across a major histocompatibility complex barrier

PloS one, 2013-10, Vol.8 (10), p.e77632

2013

Volltextzugriff (PDF)

Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I

Acta pædiatrica (Oslo), 2005-07, Vol.94 (7), p.872-877

2005

Volltextzugriff (PDF)

Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases

Journal of inherited metabolic disease, 2011-04, Vol.34 (2), p.499-508

2011

Volltextzugriff (PDF)

High dose genistein in Sanfilippo syndrome: A randomised controlled trial

Journal of inherited metabolic disease, 2021-09, Vol.44 (5), p.1248-1262

2021

Volltextzugriff (PDF)

Enzyme Replacement Therapy for Mucopolysaccharidoses: Opinions of Patients and Families

The Journal of pediatrics, 2008-05, Vol.152 (5), p.723-727

2008

Volltextzugriff (PDF)

Thoracolumbar Kyphosis in Treated Mucopolysaccharidosis 1 (Hurler Syndrome)

Spine (Philadelphia, Pa. 1976), 2014-03, Vol.39 (5), p.381-387

2014

Volltextzugriff (PDF)

Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice

Molecular genetics and metabolism, 2009-11, Vol.98 (3), p.235-242

2009

Volltextzugriff (PDF)

Evaluation of heparin cofactor II–thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice

Molecular genetics and metabolism, 2010-03, Vol.99 (3), p.269-274

2010

Volltextzugriff (PDF)

Retrovirally mediated correction of bone marrow–derived mesenchymal stem cells from patients with mucopolysaccharidosis type I

Blood, 2002-03, Vol.99 (5), p.1857-1859

2002

Volltextzugriff (PDF)

Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene

Nature genetics, 1997-10, Vol.17 (2), p.190-193

1997

Volltextzugriff (PDF)

Enzyme Replacement Therapy and Extended Newborn Screening for Mucopolysaccharidoses: Opinions of Treating Physicians

JIMD Reports - Case and Research Reports, 2011/1, 2011-01, Vol.1, p.9-15

2011

Volltextzugriff (PDF)

Laronidase treatment of mucopolysaccharidosis I

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2005, Vol.19 (1), p.1-7

2005

Volltextzugriff (PDF)

Limitations of enzyme replacement therapy: Current and future

Journal of inherited metabolic disease, 2006-04, Vol.29 (2-3), p.442-447

Wraith, J. E.

2006

Volltextzugriff (PDF)

Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I

Journal of inherited metabolic disease, 2006-02, Vol.29 (1), p.230-231

2006

Volltextzugriff (PDF)

The majority of MPS I patients tested raise inhibitory allo-antibodies against enzyme replacement therapy

Molecular genetics and metabolism, 2013-02, Vol.108 (2), p.S81-S81

2013

Volltextzugriff (PDF)

Excess Heparan Sulphate Inhibits CXCL12-Mediated Hematopoietic Cell Migration and Engraftment After Bone Marrow Transplant in Mice with Mucopolysaccharidosis Type I

Blood, 2011-11, Vol.118 (21), p.4010-4010

2011

Volltextzugriff (PDF)

Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I

Acta Paediatrica, 2005-07, Vol.94 (7), p.872-877

2005

Volltextzugriff (PDF)

Variant Gaucher disease characterized by dysmorphic features, absence of cardiovascular involvement, laryngospasm, and compound heterozygosity for a novel mutation (D409H/C16S)

American journal of medical genetics, 2002-05, Vol.109 (4), p.328-331

2002

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Aktive Filter

KollektionNexis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(42)

Publikationsform

Sprache

Englisch
(45)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease

Study of Telomere Length Reveals Rapid Aging of Human Marrow Stromal Cells following In Vitro Expansion

Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB

A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow

Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler’s syndrome after pharmacological enzyme replacement therapy

Improved Metabolic Correction in Patients with Lysosomal Storage Disease Treated with Hematopoietic Stem Cell Transplant Compared with Enzyme Replacement Therapy

Circadian rhythm and suprachiasmatic nucleus alterations in the mouse model of mucopolysaccharidosis IIIB

Signal one and two blockade are both critical for non-myeloablative murine HSCT across a major histocompatibility complex barrier

Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I

Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases

High dose genistein in Sanfilippo syndrome: A randomised controlled trial

Enzyme Replacement Therapy for Mucopolysaccharidoses: Opinions of Patients and Families

Thoracolumbar Kyphosis in Treated Mucopolysaccharidosis 1 (Hurler Syndrome)

Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice

Evaluation of heparin cofactor II–thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice

Retrovirally mediated correction of bone marrow–derived mesenchymal stem cells from patients with mucopolysaccharidosis type I

Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene

Enzyme Replacement Therapy and Extended Newborn Screening for Mucopolysaccharidoses: Opinions of Treating Physicians

Laronidase treatment of mucopolysaccharidosis I

Limitations of enzyme replacement therapy: Current and future

Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I

The majority of MPS I patients tested raise inhibitory allo-antibodies against enzyme replacement therapy

Excess Heparan Sulphate Inhibits CXCL12-Mediated Hematopoietic Cell Migration and Engraftment After Bone Marrow Transplant in Mice with Mucopolysaccharidosis Type I

Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I

Variant Gaucher disease characterized by dysmorphic features, absence of cardiovascular involvement, laryngospasm, and compound heterozygosity for a novel mutation (D409H/C16S)

Aktive Filter

Suchergebnisse filtern